• 8 April 2010
  • News
  • By

Bio Services

Syngene, Endo tie up to develop therapeutic molecules
Syngene International, a subsidiary of Biocon, has entered into a discovery and development collaboration with Endo Pharmaceuticals, US, to develop novel biological therapeutic molecules against cancer. Under the terms of the agreement, Endo will retain all rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.

Speaking on the development, Kiran Mazumdar-Shaw, CMD, Biocon Group, said, “We are very pleased to enter into this collaboration with Endo Pharmaceuticals as it showcases Syngene as an integrated custom research service provider. This agreement is also very significant considering the fact that it is for the first time in India that such a deal has been signed involving the discovery of a biological therapeutic entity.”

“We look forward to collaborating with Syngene in our efforts to discover novel treatments for oncology and deliver solutions to patients and providers. This collaboration that marks our entry into the biologics discovery space, is consistent with our strategy of building Endo's pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts,” concludes Sandeep Gupta, senior vice president of drug discovery and early development at Endo.

Bilcare research opens new unit at Crickhowell
Bilcare Global Clinical Supplies has opened its second unit in The Elvicta Industrial Estate, Crickhowell, Wales, UK. The new unit will add 30,000 sq.ft. and double the company's European capacity to package, store and distribute clinical supplies in ambient, refrigerated and frozen conditions.

Bilcare – a global company headquartered in India – established its Crickhowell site in 2006 when it purchased DHP. The Bilcare Global Clinical Supplies facility at Crickhowell is contributing to a nascent pharmaceutical 'cluster' of companies in UK.

Mohan Bhandari, chairman and MD of Bilcare Limited, said, “With the drug discovery program leading to potential new drugs becoming more complex, the need to clinically test drug efficacy and safety in diverse population groups across multiple geographic regions is becoming a crucial necessity. This necessity has led Bilcare to expand and open new facilities in the US, Europe and Asia.”

In conjunction with the expansion, Bilcare Research specializes in primary packaging for pharmaceutical products and security technology such as  nonClonable. Based on modular architecture, nonClonable enhances customer safety, improves supply chain efficiency, reduces inventory levels, and improves customer relationship management.

VLife to develop technology for NCBS
VLife Sciences Technologies has signed a contract with National Center for Biological Sciences (NCBS), Bangalore for developing a specialized modeling and simulation technology in the area of protein-protein interactions. The project is undertaken jointly by NCBS, Stanford University and Technical University of Denmark.

This project involves studying coiled coil interactions in proteins which will provide opportunity to encounter and study hitherto uncharacterized myosins, key players in the dynamic organization of cellular components. With this project, VLife has reinforced its ability to execute scientific computational work, which has made it a partner with institutes across the world.

GVK opens clinical pharmacology unit in Gujarat
GVK Biosciences (GVK BIO) has commissioned its new clinical pharmacology unit (CPU) in Ahmedabad. The new unit adds 110 beds to GVK BIO's existing capacity of 144 beds. The new CPU will conduct a variety of studies in healthy volunteers.

Ahmedabad was the most preferred and logical destination for expansion considering the volunteer pool accessibility and proximity to about 10 CROs and leading pharma companies. With three clinical wards and 110 beds, the unit is designed to suit all regulatory requirements. It also has special housing facilities for female volunteers. The unit include access to special population like young women, post-menopausal women, diseased population and access to about 12,000 healthy volunteers.

GVK BIO's CPU is a top service provider of bioequivalence studies to generic pharma companies globally. The CPU unit, operational from 2004 in Hyderabad, has undergone several international audits, inspections and has key accreditations to its credit including the USFDA, DCG(I), ANVISA (Brazil), AFSSAPS (France), WHO and the Ministry of Health, Turkey. In addition to the healthy volunteer population, the Ahmedabad facility gives access to diseased population in psychiatry, metabolism, cardiovascular and neurology.

“The facility's new CPU has been audited by the DCGI and we have initiated our first study at the Ahmedabad facility,” said Manni Kantipudi, president, GVK Biosciences.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email